Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

Highlights • The Sanofi Pasteur dengue vaccine candidate is in late-stage development. • It showed consistent safety and efficacy in ≥9 year individuals in endemic countries. • It could be an important component of integrated dengue prevention efforts. • Additional data may inform on the impact of v...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2015-12, Vol.33 (50), p.7100-7111
Main Authors: Guy, Bruno, Briand, Olivier, Lang, Jean, Saville, Melanie, Jackson, Nicholas
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Antigens
Clinical Trials as Topic
Confidence intervals
Dengue
Dengue - epidemiology
Dengue - prevention & control
Dengue fever
Dengue Vaccines - adverse effects
Dengue Vaccines - immunology
Dengue Vaccines - isolation & purification
Drug Discovery - methods
Drug Evaluation, Preclinical
Drug-Related Side Effects and Adverse Reactions
flavivirus
Humans
Immunization Schedule
Manufacturing
Quality control
Safety
Tetravalent dengue vaccine
Treatment Outcome
Vaccine
Vaccines
Vaccines, Attenuated - adverse effects
Vaccines, Attenuated - immunology
Vaccines, Attenuated - isolation & purification
Vector-borne diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The Sanofi Pasteur dengue vaccine candidate is in late-stage development. • It showed consistent safety and efficacy in ≥9 year individuals in endemic countries. • It could be an important component of integrated dengue prevention efforts. • Additional data may inform on the impact of vaccinating. • Pending licensure, post-marketing studies will further assess effectiveness and safety.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.09.108